Atlanta, GA August 6, 2019 – Emil Kakkis, MD, PhD, joins the Board of Directors for Odylia Therapeutics.  Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments  for multiple rare and ultra-rare diseases. He brings to Odylia vast knowledge...

Scott Dorfman, Odylia Therapeutics CEO, was recently a featured guest on Partners4Access Weekly Podcast.  A recording of the podcast entitled “Rare Disease, Cell and Gene Therapy Weekly Roundup” can be found here.  Produced by Partners4Access, global experts in access for orphan drug, cell and gene...